~~<i id='C74B58021F'><strike id='C74B58021F'><tt id='C74B58021F'><pre id='C74B58021F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：Wikipedia 2025-09-30 22:55:07 - browse：62

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Food as medicine: Medically tailored meals may get standardized

Wikipedia

focus

knowledge

explore

leisure time

hotspot

LaneTurner/GlobeStaffContemporarypaintingsbyartistswhohaveovercomehomelessnessordisabilitiesgreetvis

WSS

Ukraine seeks to reclaim its role as a hub for clinical trials

Donor acceptance rates hint at racial, gender bias in heart transplants: study

FDA warns medical device makers about rise in fabricated data

Ukraine seeks to reclaim its role as a hub for clinical trials

Obamacare plans could cover weight loss drugs

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

leisure time

fashion

Wikipedia

Drug repurposing or repositioning? The language matters

Ukraine seeks to reclaim its role as a hub for clinical trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Merck, Vertex, and Viking updates

Tori Bowie and the unacceptable rates of Black maternal death

Patient advocates debate FDA's accelerated approval process

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Researchers tackle phage therapy hurdles for wider adoption

focus

Opioid cravings were reduced by anti

FDA's naming rule on biosimilars has undermined competition

Why the world’s most expensive drug might be worth the price

Merck drug for rare lung condition set for approval in U.S.

Washington mulls new rules to avert another Change Healthcare

Study says nonprofit hospitals fall short in charity care spending

knowledge

explore

leisure time

hotspot